TNF-Related Apoptosis-Inducing Ligand: Non-Apoptotic Signalling.

Fiche publication

Date publication

mars 2024

Journal

Cells

Auteurs

Membres identifiés du Cancéropôle Est :
Dr MICHEAU Olivier

Tous les auteurs :
Guerrache A, Micheau O

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/38534365

Résumé

TNF-related apoptosis-inducing ligand (TRAIL or Apo2 or TNFSF10) belongs to the TNF superfamily. When bound to its agonistic receptors, TRAIL can induce apoptosis in tumour cells, while sparing healthy cells. Over the last three decades, this tumour selectivity has prompted many studies aiming at evaluating the anti-tumoral potential of TRAIL or its derivatives. Although most of these attempts have failed, so far, novel formulations are still being evaluated. However, emerging evidence indicates that TRAIL can also trigger a non-canonical signal transduction pathway that is likely to be detrimental for its use in oncology. Likewise, an increasing number of studies suggest that in some circumstances TRAIL can induce, via Death receptor 5 (DR5), tumour cell motility, potentially leading to and contributing to tumour metastasis. While the pro-apoptotic signal transduction machinery of TRAIL is well known from a mechanistic point of view, that of the non-canonical pathway is less understood. In this study, we the current state of knowledge of TRAIL non-canonical signalling.